AVTR
Avantor, Inc.11.20
-0.08-0.71%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
VWR outpaces BMP amid comps
Q&A unpacked VWR's expected growth outpacing bioscience/medtech products, pinned on tough comps in serum, electronics, and NuSil dragging the latter. Management stressed investments like $10-15M e-commerce and $20M operations are self-funded via continuous improvement, avoiding past over-cuts such as VWR specialists. Process chemicals showed book-to-bill above one excluding serum, yet supply bottlenecks persist. Q1 will be the low point. Analysts probed margins and competition; responses stayed qualitative, emphasizing rational pricing over a race to the bottom. Tone stayed transition-focused; investors watch supply fixes and revival traction.
Key Stats
Market Cap
7.64BP/E (TTM)
-Basic EPS (TTM)
-0.13Dividend Yield
0%Recent Filings
10-K
FY2025 results
Avantor's FY2025 net sales fell 3.4% to $6.6B, with organic decline of 2.8% driven by Clinical Services divestiture and softer demand in Laboratory Solutions' Total Science Solutions, though Bioscience Production held steady with semiconductor gains offsetting biopharma weakness. Q4 momentum faltered amid funding uncertainty and competition, squeezing gross margins 90bps to 32.7% from inflation and freight costs, while Adjusted Operating Income dropped 12.1% to $958M. Free cash flow contracted to $496M, yet liquidity swelled to $1.7B post-refinancing and $425M remains under a fresh buyback authorization. Cost transformation targets $400M savings by 2027. Supply chain constraints threaten quarterly execution.
8-K
Q4 sales down, segments realign
Avantor reported Q4 net sales of $1.66B, down 1% organically 4%, with full-year sales at $6.55B off 3% organically; net loss hit $530M due to $785M goodwill impairment. Revival program launches VWR brand relaunch and supply chain fixes. Segments realign to VWR Distribution & Services and Bioscience & Medtech Products effective Q1 2026. 2026 brings transition investments.
8-K
Dingemans joins Avantor board
Avantor elected Simon Dingemans, ex-CFO of GSK and Carlyle senior advisor, to its board effective January 2, 2026, replacing Jonathan Peacock who resigns December 31, 2025. Dingemans brings deep finance and biopharma expertise from Goldman Sachs and current boards at Vodafone and WPP. He qualifies as independent. Standard director pay: $95,000 cash retainer plus $210,000 RSUs vesting May 6, 2026.
8-K
Elects Mehra to board
Avantor elected Sanjeev Mehra, 66, ex-Goldman Sachs private equity veteran and Periphas Capital co-founder, to its board on December 4, 2025, with term ending at the 2026 annual meeting. He qualifies as independent under NYSE rules. Standard non-employee director pay: $95,000 annual cash retainer and $210,000 in RSUs vesting in one year. Adds deep PE expertise.
8-K
Avantor names COO Blenn
Avantor appointed Mary Blenn as Executive Vice President and Chief Operating Officer on November 10, 2025, tasking her with leading manufacturing and supply chain to boost efficiency and align with growth strategy. Blenn, ex-Cytiva SVP Global Operations, gets $500,000 base, 75% target bonus, and $5M initial equity. Newly created role. She joins under CEO Ligner amid leadership tweaks.
IPO
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
ATR
AptarGroup, Inc.
122.83+0.50
ATRC
AtriCure, Inc.
41.08+0.04
AVNT
Avient Corporation
30.50+0.02
AZTA
Azenta, Inc.
34.31-0.77
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
RSCF
Reflect Scientific, Inc.
0.05+0.00
SOAGY
Sartorius AG
56.43-0.16
WST
West Pharmaceutical Services, I
266.44-5.42